106 articles on gene editing and biotech
The eye is the ideal organ for gene editing — immune-privileged, accessible, and small. From Luxturna to in vivo CRISPR, here's how gene editing is restoring vision.
You might be 45 years old but biologically 38 — or 52. Biological age measures how fast your body is actually aging, and it can be changed. Here's how to measure and improve yours.
Duchenne muscular dystrophy affects 1 in 3,500 boys. Sarepta's Elevidys became the first gene therapy approved for DMD — but generated controversy over efficacy, safety, and its $3.2M price tag. Here's the complete picture.
Off-target editing is the biggest safety concern in gene editing. Here's how scientists detect it, measure it, and engineer around it — from high-fidelity Cas9 to prime editing's dual-check mechanism.
The same lipid nanoparticle technology that delivered COVID vaccines to billions is now delivering CRISPR to edit genes inside the body. Here's how the pandemic accelerated gene editing by a decade.
The most common question about CRISPR: is it safe? Here's what clinical trial data, FDA reviews, and peer-reviewed research actually show about the risks and side effects of gene editing in humans.
From preclinical research to FDA approval, a new therapy takes 10-15 years and costs $1-2 billion to develop. Here's what happens at each stage — and what it means if you're considering participating.
Hemgenix costs $3.5 million — the world's most expensive drug. Roctavian was withdrawn from Europe. Here's the full story of gene therapy for hemophilia: the science, the promise, and the problems.
Gene editing and gene therapy are turning 'incurable' genetic diseases into treatable — and even curable — conditions. Here are 10 diseases closest to a permanent cure.
Zolgensma was the first gene therapy to treat a leading genetic cause of infant death — and at $2.1M, one of the most expensive drugs ever created. Here's how it works, its impact, and what's next.
DNA makes RNA. RNA makes protein. This simple rule — the Central Dogma — is the foundation of all molecular biology and the reason gene editing works.
Some gene therapies last a lifetime. Others fade after a few years. Here's why durability varies, what the long-term data shows, and what it means for patients.